| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | spautin-1 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.16 | 0.005 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.33 | 0.005 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.083 | 0.006 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.006 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.007 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.15 | 0.007 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.008 |